Biodexa Pharmaceuticals Plc
BDRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.00 | -0.00 | 0.01 |
| FCF Yield | -65.01% | -4,344.05% | -704.70% | -131.67% |
| EV / EBITDA | -2.10 | 0.75 | 0.15 | 0.79 |
| Quality | ||||
| ROIC | -85.12% | -147.40% | -212.80% | -55.78% |
| Gross Margin | 0.00% | -967.45% | -631.19% | -705.19% |
| Cash Conversion Ratio | 2.14 | 0.96 | 0.92 | 1.10 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -12.97% | 26.78% | -4.99% |
| Free Cash Flow Growth | -83.88% | 0.30% | -12.36% | 33.46% |
| Safety | ||||
| Net Debt / EBITDA | 0.10 | 0.77 | 0.27 | 1.64 |
| Interest Coverage | 0.00 | -195.46 | -168.53 | -159.05 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | -5.78 | 0.00 | 0.00 |
| Cash Conversion Cycle | -47.46 | 583.07 | 147.59 | -17.20 |